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Unique activation of matrix metalloproteinase-9 within
human liver metastasis from colorectal cancer
ZS Zeng and JG Guillem
Colorectal Service. Department of Surgery. Memorial Sloan-Kettering Cancer Center. 1275 York Avenue. New York. NY 10021. USA
Summary Expermental in vitro and animal data support an important role for matrix metalloproteinases (MMPs) in cancer invasion and
metastasis via proteolytic degradation of the extracellular matrix (ECM). Our previous data have shown that MMP-9 mRNA is localized to the
interface between liver metastasis and normal liver tissue, indicating that MMP-9 may play an important role in liver metastasis formation. In
the present study, we analysed the cellular enzymatic expression of MMP-9 in 18 human colorectal cancer (CRC) liver metastasis specimens
by enzyme-linked immunosorbent assay (ELISA) and zymography. ELISA anatysis reveals that the latent form of MMP-9 is present in both
liver metastasis and paired adjacent normal liver tissue. The mean level of the latent form of MMP-9 is 580±270 ng per mg total tissue protein
(mean ± s.e.) in liver metastasis vs 220 ± 90 in normal liver tissue. However, this difference is not significantly different (P= 0.26). Using
gelatin zymography, the 92-kDa band representative of the latent form is present in both liver metastasis and normal livertissue. However, the
82 kDa band, representive of the active form of MMP-9, was seen only in liver metastasis. This was confirmed by Westem blot analysis. Our
observation of the unique presence of the active form of MMP-9 within liver metastasis suggests that proMMP-9 activation may be a pivotal
event during CRC liver metastasis formation.
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Colorectal cancer (CRC) is the third most common malignancy
in the United States. with an estimated 131 200 new cases and
54 900 deaths in 1997 (Parker et al. 1997). The lixer is the most
common site for blood-borne metastasis. Aith 15% of CRC
patients harbounng liver metastasis at diagnosis and 60% ofthese
patients haxing lixer-only or li-er-predominant disease (Kemeny
and Seiter. 1993).
Lixer metastasis formation is a complex. multifactorial. multi-
stage process. requinng degradation of the extracellular matrix
(ECM). breach of basement membrane. tumour cell intravasation
and extraxasion of the vascular sy-stem and colonization of the
liver. This process is likely to inxolxve numerous proteolytic
enzy-mes. including, the matrix metalloproteinases (MMPs). a
family of Zn>- endopeptidases capable of degrading ECM (Liotta
and Stetler-Stevenson. 1991: Matrisian. 1992).
Increased metastatic capacity follow-ing transfection of MNP-9
into Ha-ras + ElA-transformed cells supports a causal role for
MMP-9 in metastasis fornation (Bernhard et al. 1994). In addition.
elexvated MMP-9 actixvitx in experimental colon tumours trans-
planted into mice has been shown to correlate with metastasizinc
(Nakajima et al. 1990). Furthermore. oxerexpression of MMP-9
has been obser ed in x-arious human cancers. includinc CRC (1Px ke
et al. 1993: Liabakk et al. 1996: Nielsen et al. 1996: Zeng and
Guillem. 1996). breast (Davies et al. 1993a). bladder (Davies et al.
1993b). prostate (Hamdy et al. 1994). lunc (Brown et al. 1993a .
squamous cell carcinoma ([N-ke et al. 1992) and brain tumours (Rao
et al. 1993 Our recently published data hax-e shown that tumour
tissue MMP-9 RNA lex-el can predict colorectal cancer relapse and
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survixal (Zeng et al. 1996). emphasizing the clinical importance of
elevated MMP-9 expression in primarx CRC.
We hax-e previously demonstrated that MMP-9 mRRNA is local-
ized in the interface between lixer metastasis and normal lixer
tissue. indicating that MMP-9 may play an important role in lix er
metastasis formation. To inxestigate further the significance of
elexated MMP-9 RNA in liver metastasis formation. the present
study examined MMP-9 enzy matic expression in CRC liver
metastasis.
MATERIALS AND METHODS
Human tissue process
Eighteen lix er metastases from CRC and paired normal liver tissue
were obtained from the operating room immediately after resec-
tion with the approval of the Institutional Reviex- Board of the
Memorial Sloan-Ketterinc Cancer Center. Theywxere quick frozen
in liquid nitrogen and stored at -80 C until processed. The pres-
ence oflixver metastasis was confirmed by pathological assessment
on haematoxyvlin- and eosin-stained paraffin sections. Tissue wxas
homogenized in Tris buffer [50 m-t Tris-HCl. pH 7.5. containing
75 mr sodium chloride. 1% Triton. 0.1I%c sodium dodecyl sulphate
(SDS)] and centrifuged at 5000g for 20 min at 4"C as prexiously
described (Zeng and Guillem. 1996). Protein concentration of the
supernatant was deterrmined xxith protein assay reagent according
to the manufacturer's instruction (Bio-Rad Laboratories. Hercules.
CA. USA). The supernatant of liver metastasis and paired nornal
lixver tissue were used for ELISA and zymography.
ELISA plate assay
Quantification of MMP-9 lexels in liver metastasis and normal
lixer tissue wxas performed by the Biotrak MMP-9 ELISA kit
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Figure 1 Comparative distnbution of ProMMP-9 levels in liver metastasis and normal liver tissue from 18 colorectal cancer patients with liver metastasis
determined by ELISA analysis. *. Liver metastasis: _. normal liver
Amersham International. UK). T%-o monoclonal antibodies, both
recognizing pro-NM\IP-9. vvere used for this assa,. The methods
used wx-ere those descnibed in the protocol accompanving the
ELISA kit. Briefl. 60 ug of total protein Xwas added to each xwell
in duplicate. The plates xwere incubated at room temperature
for exactIv 1 h. After xxashing four times xxith xwash buffer
(0.01 Ni phosphate buffer. pH 7.0. containing 0.05Cc Twxeen 20 a
l ophilized anti-NIMP-9 antibodv conjugated to horseradish
peroxidase xwas added and incubated at room temperature for 2 h.
After another \xvash. TMIB substrate wx-as added into each xxweli and
follow-ed xxvith constant shaking at room temperature for exactly
30 min. The optical densit GOD XX -as determined at 450 nm.
Gelatin zymography
Eight per cent SDS-polvacrxlamide electrophoretic gels co-poly-
merized x\ith 1 mg ml-: gelatin xvere used to detect both latent and
activated forms of gelatinase. Equal amounts of total protein
125 ug per lane of tumour and paired normal liver xvere loaded
into separate lanes and separated by electrophoresis under non-
denaturino conditions. The gels xxere X\ashed txx ice in 2.5Cc Triton
X-l00 TX-I00) for 30 rmnn at room temperature to remoxe SDS.
Zvmoarams xwere subsequentlv dexeloped by incubation oxernioht
at 37C in collagenase buffer i0.2 Ni sodium chlonrde. 5 m-I
calcium chlonrde. 1 Cc vol/xJol TX- 00 and 0.02-c- sodium azide in
50 mMI Tris-HCl pH /.4). Zvmograms xere stained Xwith 1 X
Coomassie blue G-250 diSsolsxed in 30Wc methanol containina
10Cc -/x- glacial acetic acid at room temperature for 3 h. Gel X -as
destained in the same solution but xwithout the Coomassie blue
stain. Gelatinolxtic actixity xvas xisualized as a clear band a2ainst
a dark background of stained oelatin.
9^--kDa aelatinase control consisted of a medium conditioned
bx RA3-1 S7 cells that xwere derixed from pnrmar- rat embrvo
fibroblasts bv co-transfection xx-ith the Ha-ras and adenoxvirus EJ-A
oncogenes kindlI prox ided b\ Dr RJ Muschel 1.
Western blot analysis
These xxere carned out as prexiously described iZeng et al. 1994).
The supematant of lixer metastases and paired normal lixver
25 ug xx ere electrophoresed on an 8'-c SDS-PAGE gel using a
Minigel apparatus Bio-Rad. Richmond. CA. USA). Separated
proteins xx ere transferred to nitrocellulose membranes Amersham.
Buckinghamshire. UK in Tri's-lx-cine buffer 2.5 msi Tris.
192 mnw al! cine and 20Cc methanol at 4AC and 100 \ using a Mini
sxystem. Non-specific binding sites x- ere blocked for 1 h at room
temperature xwith a solution containing 4Cc bovine serum albumin.
The blots xx ere incubated overnight at 4-C in a solution containing
polyclonal rabbit antihuman MMP-9 antibody Ab 110 I proxided by
Dr William G Stetler-Stexvenson. Laborator- ofPathologv. National
Cancer Institute). The blot vx-as xxashed sexeral times wxith TBS-T.
folloxx ed b\- an incubation step X -ith horseradish peroxidase
labelled anti-rabbit antibodx 11:5000 in TBS-T for 30 min in room
temperaturei. Reactixe proteins xwere xisualized xxith an enhanced
chemiluminescence detection sxstem ECL. Amersham as
described bx the manufacturer.
RESULTS
ProMMP-9 protein in liver metastasis quantified by
ELISA assay
The results of MMP-9 ELISA analvs-is are shoxxn in Figure 1.
Pro-MIMP-9 xx as obserxed in all 18 CRC lix er metastases and
paired normal lixer samples. In 8 of the 18 caseS. proMNIMP-9 in
lixer metastasis xxas hiaher than in normal lixer tissue caes 2. 4.
7. 8. 9. 10. 11 and 13.. In sexven cases. the lexels of proMNIMP-9
protein in lixer metastasis xxwere nearly equal to those in normal
lixer tissue icases 1. 3. 5. 12. 15. 17 and 18. In three patients.
proNI\IP-9 lexels xxere much higher in normal lixer tissue than in
lixer metastasis cases 6. 14 and 16i. The lexels of proMNIMP-9 in
lix-er metastasis xaried from 20 to 750 ng mg: total tissue protein
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Figure 2 Comparison of ProMMP-9 levels in liver metastasis and normal
liver tissue. Data are expressed as mean of MMP-9 - s.e. E. liver metastasis
normal liver. P= 0.26
wxith a mean proMNM-P-9 lexel of 580 ± 270 ng mg- total tissue
protein (mean + s.e. i. The corresponding range for proMNIP-9 in
paired normal lixer tissue wxas 30-1690 ng mg-: protein xxith the
mean xalue of 220 90 ng mg- protein in normal lixier respec-
tixelv. Howex-er. as seen in Fisure 2 this difference does not reach
significance (P = 0.26).
Zymographic detection of active and latent MMP-9
forms
Gelatin zymography detected both the pro and actix-e forms of
NIMP-9 xPith molecular xxweights of 92 and 82 kDa respectix-ely.
The identitx of these activities xvas confirmed wx-ith molecular
W-eight standards and the 92-kDa gelatinase positix-e control
(medium conditioned bv RA3-1S7 cells). The 92-kDa latent form
of MMNIP-9 (proMNMIP-9() was detected in both liver metastasis and
paired normal liver samples. As show-n in Figure 2. the activated
form of MNIP-9 w-as seen onlx in liver metastasis. whereas no
active MNIP-9 activitV could be detected by zymography in
normal lixer. Fourteen of 18 (77.8 c( liver metastasis samples
(cases 1. 2. 4. 5. 6. 8. 9. 10-16) expressed actixated forms of
MIMP-9 (82 kDa). MNIP-9 gelatinase activity in liver metastasis
and normal liver x-as confirmed by complete inhibition of activitV
w-hen duplicate gels wxere incubated in the presence of 10 mm
EDTA (data not show-n). To test the possibilitx- of spontaneous
actixvation of gelatinases during sample storage. xwe selected txwo
paired lixer metastases and corresponding normal lixer samples
(cases 17 and 18). both lackin2 the actix-e MMP-9 form. and
performed gelatin zymography 1 wxeek. half a month and 1 month
after storage at -80^C. Despite prolonged storage. no actixe form
w-as detected in both lixver metastasis and lixver (data not shoxn).
Western blot confirmation of active MMP-9
To confirm that the 82 kDa band seen in the gelatin zymography
represented activated MIMP-9. MNIP-9 protein expression wxas
detected bv Western blot analvsis using MNIMP-9 antibodv Ab 110.
wxhich recognizes both the latent and actixated formn of MNIP-9.
Figure 4 showxs a representatixe Western blot of MNIP-9 from lix er
metastasis and corresponding normal lixver samples (cases 9-121.
In agreement wxith zxmograpy. the 92-kDa band ofproMMNIP-9 wxas
observed in both lixer metastases and normal lixer tissue. The
MNIP-9 form. wxhich is detected in tumours. appears to correspond
specifically to the actixvated form of MMNIP-9 (82 kDa). There is
verv little. ifanx. actix ated forn ofNIMP-9 in normal lix-er tissue.
DISCUSSION
Ourprexious x ork and that ofothers hax-e demonstrated that lexels
of actixated MNIP-2 and NIMP-9 correlate xith progression of
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Figure 3 MMP-9 enzymatic activities in human colorectal cancer liver metastasis detected by zymography. Control lane. 25 ug of conditional medium from
RA3.1S7: LM. liver metastasis: N. normal liver bssue. Case numbers are shown above each matching tumour-normal pair. The positions of pro and active
MMP-9 forms (92 kDa and 82 kDa bands) are noted by arrows. Liver metastasis (LM) and normal liver tissue (N) extracts (25 ug) from each patient were
separated on a 10%c sodium dodecyl sulphate (SDS)-polyacrylamide gel containing 1 mg ml- gelabn
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FKgure 4 Western blot analysis of MMP-9 in CRC liver metastasis. Liver
metastasis (LM) and adacent normal liver tissue (N) extracts from each
patient were separated on 8% SDS-PAGE gel and trarsferred to
nitrocellukse membranes. The membrane was Wixubated with polydonal
rabbit antihuman MMP-9 antibodbes Ab110 and visualized as descrbed in
Material and methods. The posibon of proMMP-9 and its activated form,
82 kDa collagenase, are noted by arrows
several human malignant tumours including CRC (Rajabi et al.
1990; Zeng et al. 1995). lung cancer (Brown et al. 1993b), breast
cancer (Davies et al, 1993a). gastric cancer (Rajabi et al. 1990).
prostate cancer (Stearns and Wang. 1993) and melanoma
(MacDougall et al. 1995). The present study provides clear
evidence that the activated form of MMP-9 is detected only in
liver metastasis. not in adjacent normal livertissue. suggesting that
MMP-9 activation is a pivotal event during CRC liver metastasis
formation.
The precise mechanism by which MMP-9 is synthesized and
secreted remains unknown. However, it has become apparent that
the intracellular signalling events controlling MMP-9 production
are likely to involve tumour-stroma cellular interactions. As
MMP-9 is secreted in a latent form, activation must occur in order
to ensure extracellular matrix substrate degradation. This is
accomplished by cleavage at the Glu-40-Met-41 amide bond
located in the middle of the propeptide to generate an 86-kDa
intermediate. Cleavage ofthis bond triggers achange in proMMP-
9 that renders the Arg-87-Phe-88 amide bond susceptible to the
second cleavage, resulting in conversion to an 82-kDa species
(Ogata et al. 1992: Fridman et al, 1995). ProMMP-9 can be acti-
vated autocatalytically by organomercurial compounds or trypsin
in vitro (Wilhelm et al, 1989; Lyons et al, 1991). In the current
study. the possibility of spontaneous activation of gelatinases in
liver metastasis during sample processing appears to be unlikely,
as the liver metastasis and control normal liver samples were
processed in an identical manner and run on the same gel. In addi-
tion, tissue samples initially negative for the active 82-kDa band
remained negative despite storage and repeat analysis at different
time points.
Several studies have demonstrated that MMPs have the ability
to activate one another (Ogata et al, 1992; O'Connell et al, 1994;
Cao et al. 1995: Fridman et al, 1995). Stromelysin (MMP-3) has
been shown to activate proMMP-9, and ProMMP-3 can be acti-
vated by plasmin and cathepsin B. MT-MMPs, which are found on
the cell membrane of tumour cells, have been shown to activate
MMP-2 (Sato et al. 1994). The complex ofproMMP-2 andTTIMP-
2 binds to activated MT-MMP and this binding ultimately results
in activation of MMP-2 (Himelstein et al, 1994; Cao et al. 1995).
The active MMP-2 species may in turn activate proMMP-9
(Fridman et al. 1995). Taken together. the process ofMMP-9 acti-
vation may be similarto the blood-clotting cascade. Co-expression
ofthese enzymes in tumour tissue would facilitate their interaction
for activation, leading to degradation of ECM (Fridman et al.
1995). It is interesting that our previous data demonstrated a
significant increase in MMP-9 RNA expression in human liver
metastasis when compared with nornal liver tissue by Northem
blot and in situ hybridization (Zeng and Guillem, 1995). However.
ELISA and zymographic analysis detect pro-MMP-9 enzyme in
both liver metastasis and normal liver tissue. It is difficult to
explain this inconsistency. except that there may be factors that
control both MMP-9 RNA up-regulation and proenzyme activa-
tion. In addition. MMP-9 activation in liver metastasis was not
uniform (78% ratherthan 100%). supporting the notion that MMP-
9 activation may not be the only mechanism involved in liver
metastasis formation.
Our in situ and immunohistochemistry data indicate MMP-9
production by macrophages in liver metastasis (Zeng and
Guillem. 1995). Because not all macrophages contain detectable
amounts of MMP-9. this may be due to differences among
various macrophage subpopulations (Heuff et al, 1993). It is
reported that tumour-associated macrophages (TAMs) may be
involved in the development of liver metastasis (Martin et al.
1989: Heuff et al. 1993). Heuff et al (1993) observed tumour-
infiltrating macrophages. a peculiar type of TAM. in a rat liver
metastasis model. As many tumours produce factors such as
macrophage colony-stimulating factor (M-CSF) (Walter et al.
1991) and as TAM may bear receptors for M-CSF (Bottazi et al.
1990), tumour cells may stimulate the migration and growth of
tumour-associated macrophages to the tumour edge, leading to
increased local MMP-9 production facilitating tumour invasion.
This notion is supported by the identification of agents such as
lipopolysaccharide (LPS), which can stimulate macrophages to
produce several MMPs including MMP-9 (Welgus et al. 1990;
Xie et al. 1994). as well as our work, which demonstrates that
metastastic CRC cells can stimulate THP-1 monocytes to
produce MMP-9 (Swallow et al. 1996). Further support for an
important role of macrophage-derived MMPs in invasion comes
from studies using macrophage metalloproteinase (MMP-12 or
MME)-deficient mice (MME-/-). Macrophages of MME-/-
mice have a markedly diminished capacity to degrade ECM
components. MME-/- macrophages are essentially unable to
penetrate reconstituted basement membrane in vitro or in vivo
(Shipley et al, 1996).
In conclusion, our results demonstrate the presence of
proMMP-9 in both liver metastasis and normal liver tissue.
However, the active form of MMP-9 is detected only in liver
metastasis. These results support the notion that proMMP-9 acti-
vation is a pivotal event during liver metastasis formation. An
enhanced understanding of the molecular mechanisms respon-
sible for the activation of pro-MMP-9 may lead to the develop-
ment of novel methods for the prevention and treatment of liver
metastasis.
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